Atypical mycobacteriosis : new drugs, new strategies

L. Casali (Pavia, Italy)

Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease
Session: PG11 - Multiresistant tuberculosis and atypical mycobacterial disease
Session type: Postgraduate Course
Number: 25
Disease area: Respiratory infections

Slide presentationPDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Casali (Pavia, Italy). Atypical mycobacteriosis : new drugs, new strategies. Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
The challenges of severe pneumonia: new pathogens, new drugs and new formulations
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021

Treating sarcoidosis and potential new drugs
Source: Eur Respir Monogr 2022; 96: 328-336
Year: 2022

Bronchiectasis: new therapies and perspectives
Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment
Year: 2018

Novel NTM treatments and approaches, repurposed to bacteriophages
Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment
Year: 2021

Malignant mesothelioma: new treatment advances, including targeted therapies
Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care
Year: 2021

Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?
Source: Eur Respir J 2013; 42: 1449-1453
Year: 2013

Rational use of new TB drugs in the EU
Source: Annual Congress 2012 - New guidelines in respiratory infections
Year: 2012

Tuberculosis elimination, patients' lives and rational use of new drugs: revisited
Source: Eur Respir J 2016; 47: 664-667
Year: 2016

Collapse therapy using endobronchial valves as a new approach to treat cavities in MDR tuberculosis and selected cases of mycobacteriosis: Case series report
Source: International Congress 2015 – Advances in therapeutic bronchoscopy
Year: 2015

Novel drugs against tuberculosis: a clinician's perspective
Source: Eur Respir J 2015; 45: 1119-1131
Year: 2015

MDR-TB management: what is new?
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019
Year: 2019

Therapeutic options for sarcoidosis: old and new
Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005
Year: 2005

Rare pulmonary disease and orphan drugs: a path to the future
Source: Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019
Year: 2019

HAP/VAP : new guidelines, new approaches
Source: International Congress 2018 – Chinese Programme 2018: Part II
Year: 2018

From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections
Source: International Congress 2017 – Scientific year in review
Year: 2017

Facts and perspectives in the development of new anti-TB drugs
Source: Annual Congress 2008 - New insights into tuberculosis control
Year: 2008

Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity
Source: International Congress 2014 – Tuberculosis: diagnosis
Year: 2014